Literature DB >> 23280123

An aggregated analysis of hormonal factors and endometrial cancer risk by parity.

Sara J Schonfeld1, Patricia Hartge, Ruth M Pfeiffer, D Michal Freedman, Robert T Greenlee, Martha S Linet, Yikyung Park, Catherine Schairer, Kala Visvanathan, James V Lacey.   

Abstract

BACKGROUND: Nulliparity is associated with an increased risk of endometrial cancer. It is less clear whether nulliparity modifies the association between other established hormone-related risk factors. The proportion of nulliparous women has increased since the mid-1970s, but most individual studies to date have been too small to test the hypothesis that endometrial cancer risk factors may be associated more strongly with risk among nulliparous women compared with parous women.
METHODS: Data were aggregated on 26,936 postmenopausal, Caucasian, nulliparous women (360 endometrial cancers) and 146,583 postmenopausal, Caucasian, parous women (1378 endometrial cancers) from 4 US prospective studies (1979-2006). Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated in stratified analyses.
RESULTS: The risk of endometrial cancer was higher among nulliparous women than among parous women, as expected (nulliparous vs parous: HR, 1.42; 95% CI, 1.26-1.60). Stratified associations between endometrial cancer and hormone-related risk factors did not differ between nulliparous versus parous women: For both groups, oral contraceptives and earlier menopause were associated with reduced risk. The highest HRs were for obesity: A body mass index ≥30 kg/m(2) (vs <25 kg/m(2) ) increased the risk of endometrial cancer 3-fold among nulliparous women (HR, 3.04; 95% CI, 2.34-3.94) and parous women (HR, 2.88; 95% CI, 2.52-3.29).
CONCLUSIONS: The results from this large, pooled analysis of data from 4 large prospective studies suggested that nulliparity does not modify the risks of endometrial cancer associated with established hormone-related risk factors.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23280123      PMCID: PMC3744666          DOI: 10.1002/cncr.27909

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

Review 1.  Hormonal carcinogenesis.

Authors:  B E Henderson; H S Feigelson
Journal:  Carcinogenesis       Date:  2000-03       Impact factor: 4.944

2.  Design and serendipity in establishing a large cohort with wide dietary intake distributions : the National Institutes of Health-American Association of Retired Persons Diet and Health Study.

Authors:  A Schatzkin; A F Subar; F E Thompson; L C Harlan; J Tangrea; A R Hollenbeck; P E Hurwitz; L Coyle; N Schussler; D S Michaud; L S Freedman; C C Brown; D Midthune; V Kipnis
Journal:  Am J Epidemiol       Date:  2001-12-15       Impact factor: 4.897

3.  Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development.

Authors: 
Journal:  JAMA       Date:  1987-02-13       Impact factor: 56.272

4.  Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer.

Authors:  Amanda I Phipps; Jennifer A Doherty; Lynda F Voigt; Deirdre A Hill; Shirley A A Beresford; Mary Anne Rossing; Chu Chen; Noel S Weiss
Journal:  Cancer Causes Control       Date:  2011-09-11       Impact factor: 2.506

5.  Why is parity protective for uterine fibroids?

Authors:  Donna Day Baird; David B Dunson
Journal:  Epidemiology       Date:  2003-03       Impact factor: 4.822

6.  Two pathogenetic types of endometrial carcinoma.

Authors:  J V Bokhman
Journal:  Gynecol Oncol       Date:  1983-02       Impact factor: 5.482

7.  Cancer incidence in the US radiologic technologists health study, 1983-1998.

Authors:  Alice J Sigurdson; Michele Morin Doody; R Sowmya Rao; D Michal Freedman; Bruce H Alexander; Michael Hauptmann; Aparna K Mohan; Shinji Yoshinaga; Deirdre A Hill; Robert Tarone; Kiyohiko Mabuchi; Elaine Ron; Martha S Linet
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

8.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

Authors:  Adam L Hersh; Marcia L Stefanick; Randall S Stafford
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

9.  Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies.

Authors:  G L Rubin; H B Peterson; N C Lee; E F Maes; P A Wingo; S Becker
Journal:  Am J Obstet Gynecol       Date:  1990-01       Impact factor: 8.661

10.  The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk.

Authors:  T J Key; M C Pike
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

View more
  15 in total

1.  Intra-Individual Consistency in Endocrine Profiles Across Successive Pregnancies.

Authors:  Molly Fox; Curt A Sandman; Elysia Poggi Davis; Laura M Glynn
Journal:  J Clin Endocrinol Metab       Date:  2015-10-20       Impact factor: 5.958

2.  Reproductive factors and incidence of endometrial cancer in U.S. black women.

Authors:  Todd R Sponholtz; Julie R Palmer; Lynn Rosenberg; Elizabeth E Hatch; Lucile L Adams-Campbell; Lauren A Wise
Journal:  Cancer Causes Control       Date:  2017-03-30       Impact factor: 2.506

3.  Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2).

Authors:  Michele L Cote; Tala Alhajj; Julie J Ruterbusch; Leslie Bernstein; Louise A Brinton; William J Blot; Chu Chen; Margery Gass; Sarah Gaussoin; Brian Henderson; Eunjung Lee; Pamela L Horn-Ross; Laurence N Kolonel; Andrew Kaunitz; Xiaolin Liang; Wanda K Nicholson; Amy B Park; Stacey Petruzella; Timothy R Rebbeck; V Wendy Setiawan; Lisa B Signorello; Michael S Simon; Noel S Weiss; Nicolas Wentzensen; Hannah P Yang; Anne Zeleniuch-Jacquotte; Sara H Olson
Journal:  Cancer Causes Control       Date:  2014-12-23       Impact factor: 2.506

4.  Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome.

Authors:  Seyedeh Ghazaleh Dashti; Rowena Chau; Driss Ait Ouakrim; Daniel D Buchanan; Mark Clendenning; Joanne P Young; Ingrid M Winship; Julie Arnold; Dennis J Ahnen; Robert W Haile; Graham Casey; Steven Gallinger; Stephen N Thibodeau; Noralane M Lindor; Loïc Le Marchand; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win
Journal:  JAMA       Date:  2015-07-07       Impact factor: 56.272

5.  Body Size, Metabolic Factors, and Risk of Endometrial Cancer in Black Women.

Authors:  Todd R Sponholtz; Julie R Palmer; Lynn Rosenberg; Elizabeth E Hatch; Lucile L Adams-Campbell; Lauren A Wise
Journal:  Am J Epidemiol       Date:  2016-01-27       Impact factor: 4.897

Review 6.  Association of Combined Estrogen-Progestogen and Progestogen-Only Contraceptives with the Development of Cancer.

Authors:  William V Williams; Louise A Mitchell; S Kathleen Carlson; Kathleen M Raviele
Journal:  Linacre Q       Date:  2019-01-03

7.  Comparison of Age- Standard Incidence Rate Trends of Gynecologic and Breast Cancer in Iran and Other Countries.

Authors:  Maliheh Arab; Giti Noghabaei
Journal:  Iran J Public Health       Date:  2014-10       Impact factor: 1.429

8.  Parity Correlates with the Timing of Developing Endometrial Cancer, But Not Subtype of Endometrial Cancer.

Authors:  Qi Chen; Mancy Tong; Fang Guo; Sandy Lau; Min Zhao
Journal:  J Cancer       Date:  2015-09-03       Impact factor: 4.207

9.  Harmonisation of biobanking standards in endometrial cancer research.

Authors:  M Adishesh; A Fyson; S B DeCruze; J Kirwan; H M J Werner; D K Hapangama
Journal:  Br J Cancer       Date:  2017-06-29       Impact factor: 7.640

10.  Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium.

Authors:  Ashley S Felix; Mia M Gaudet; Carlo La Vecchia; Christina M Nagle; Xiao Ou Shu; Elisabete Weiderpass; Hans Olov Adami; Shirley Beresford; Leslie Bernstein; Chu Chen; Linda S Cook; Immaculata De Vivo; Jennifer A Doherty; Christine M Friedenreich; Susan M Gapstur; Dierdre Hill; Pamela L Horn-Ross; James V Lacey; Fabio Levi; Xiaolin Liang; Lingeng Lu; Anthony Magliocco; Susan E McCann; Eva Negri; Sara H Olson; Julie R Palmer; Alpa V Patel; Stacey Petruzella; Jennifer Prescott; Harvey A Risch; Lynn Rosenberg; Mark E Sherman; Amanda B Spurdle; Penelope M Webb; Lauren A Wise; Yong-Bing Xiang; Wanghong Xu; Hannah P Yang; Herbert Yu; Anne Zeleniuch-Jacquotte; Louise A Brinton
Journal:  Int J Cancer       Date:  2014-09-30       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.